In a recent tweet, the Indian Council of Medical Research (ICMR)
informed that COVAXIN is effective against double mutant strains and other widespread variants.
Made-in-India vaccine, Covaxin neutralizes a wide range of SARS-CoV-2 variants and effectively neutralises the double mutant strain.
ICMR- National institution of Virology have successfully isolated and cultured multiple variants of concerns of the SARS-CoV-2 virus. These include the Brazil variant, South African variant and UK variant.
The findings of the study show that COVAXIN, indigenously manufactured by Bharat Biotech is effective for B.1.617 SARS-CoV-2 that is found in India and several other countries.
ICMR NIV has demonstrated the neutralization potential of COVAXIN against the UK variant and Brazil variant.
Amidst the racing COVID-19 cases and the panic, the ICMR’s study came in as a sigh of relief.
India’s Covaxin has received Emergency Use Authorizations (EUAs) for COVID-19 treatment in India and several countries across the globe with many in the pipeline.
India is boosting this vaccine production and through the mass vaccination drive, people are already receiving the effective Bharat Biotech’s Covaxin.
In a recent statement, Bharat Biotech has said that they have increased the manufacturing capacity of COVAXIN, to 700 million doses per annum.
Manufacturing scale-up has been carried out in a stepwise manner across multiple facilities at Hyderabad and Bangalore, the company said in a statement.